HC Wainwright Predicts Higher Earnings for Fate Therapeutics

Fate Therapeutics, Inc. (NASDAQ:FATE) – Stock analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of Fate Therapeutics in a report released on Monday, May 4th. HC Wainwright analyst R. Burns now anticipates that the biopharmaceutical company will earn ($0.28) per share for the quarter, up from their previous forecast of ($0.30). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Fate Therapeutics’ Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($1.17) EPS.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.27) EPS for the quarter, meeting the consensus estimate of ($0.27). The business had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $1.20 million. Fate Therapeutics had a negative return on equity of 55.02% and a negative net margin of 2,051.08%.

Separately, Weiss Ratings lowered Fate Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 29th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $4.50.

Fate Therapeutics Trading Up 31.1%

Shares of NASDAQ:FATE opened at $2.36 on Wednesday. The stock has a market capitalization of $274.42 million, a PE ratio of -2.05 and a beta of 2.13. Fate Therapeutics has a 1 year low of $0.91 and a 1 year high of $2.36. The firm has a fifty day moving average price of $1.31 and a 200 day moving average price of $1.21.

Institutional Trading of Fate Therapeutics

Large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company bought a new stake in Fate Therapeutics during the fourth quarter valued at about $35,000. Corient Private Wealth LLC bought a new stake in shares of Fate Therapeutics in the 4th quarter worth approximately $29,000. Bridgeway Capital Management LLC acquired a new stake in Fate Therapeutics during the second quarter worth $28,000. Commonwealth Equity Services LLC acquired a new stake in shares of Fate Therapeutics during the 4th quarter valued at about $26,000. Finally, SG Americas Securities LLC boosted its holdings in Fate Therapeutics by 105.9% during the first quarter. SG Americas Securities LLC now owns 80,139 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 41,226 shares in the last quarter. 97.54% of the stock is owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.